Clinical Trial: Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds

U.S., Dec. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07265791) titled 'Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds' on Nov. 24.

Brief Summary: Study of JTM104 Injection vs. Juvederm in Treating Moderate to Severe Nasolabial Folds

Study Start Date: Jan. 03, 2026

Study Type: INTERVENTIONAL

Condition: Nasolabial Folds, Wrinkles

Intervention: BIOLOGICAL: JTM104

JTM104 contains 22.8 mg/mL cross-linked hyaluronic acid, 1.2 mg/mL hyaluronic acid, and 3 mg/mL lidocaine. The product will be injected into the nasolabial folds, with a maximum volume of 1 mL per side.

BIOLOGICAL: Juvederm(R) ULTRA PLUS XC

Juvederm(R) ULTRA PLUS XC contains 22.8 mg/mL cross-linked ...